Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR mHealth and uHealth

Date Submitted: Nov 4, 2020
Date Accepted: Jan 22, 2021

The final, peer-reviewed published version of this preprint can be found here:

The Potential of mHealth as a Game Changer for the Management of Sickle Cell Disease in India

Kumar R, Das A

The Potential of mHealth as a Game Changer for the Management of Sickle Cell Disease in India

JMIR Mhealth Uhealth 2021;9(4):e25496

DOI: 10.2196/25496

PMID: 33847598

PMCID: 8080143

Can mHealth be the gamechanger for management of Sickle Cell Disease in India?

  • Ravindra Kumar; 
  • Aparup Das

ABSTRACT

Sickle cell disease is a chronic genetic disease and requires lifelong therapy and monitoring. Low drug adherence and monitoring may lead to increase morbidities and poor quality of life. In the era of digital health, various mHealth applications are being tested for increasing drug adherence in sickle cell disease patients. We herewith discuss the feasibility of these mHealth applications in management of sickle cell disease in India.


 Citation

Please cite as:

Kumar R, Das A

The Potential of mHealth as a Game Changer for the Management of Sickle Cell Disease in India

JMIR Mhealth Uhealth 2021;9(4):e25496

DOI: 10.2196/25496

PMID: 33847598

PMCID: 8080143

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.